Literature DB >> 26084343

Intake of Lactobacillus reuteri improves incretin and insulin secretion in glucose-tolerant humans: a proof of concept.

Marie-Christine Simon1, Klaus Strassburger2, Bettina Nowotny1, Hubert Kolb3, Peter Nowotny1, Volker Burkart1, Fariba Zivehe1, Jong-Hee Hwang1, Peter Stehle4, Giovanni Pacini5, Bolette Hartmann6, Jens J Holst6, Colin MacKenzie7, Laure B Bindels8, Ines Martinez8, Jens Walter9, Birgit Henrich7, Nanette C Schloot10, Michael Roden11.   

Abstract

OBJECTIVE: Ingestion of probiotics can modify gut microbiota and alter insulin resistance and diabetes development in rodents. We hypothesized that daily intake of Lactobacillus reuteri increases insulin sensitivity by changing cytokine release and insulin secretion via modulation of the release of glucagon-like peptides (GLP)-1 and -2. RESEARCH DESIGN AND METHODS: A prospective, double-blind, randomized trial was performed in 21 glucose-tolerant humans (11 lean: age 49 ± 7 years, BMI 23.6 ± 1.7 kg/m(2); 10 obese: age 51 ± 7 years, BMI 35.5 ± 4.9 kg/m(2)). Participants ingested 10(10) b.i.d. L. reuteri SD5865 or placebo over 4 weeks. Oral glucose tolerance and isoglycemic glucose infusion tests were used to assess incretin effect and GLP-1 and GLP-2 secretion, and euglycemic-hyperinsulinemic clamps with [6,6-(2)H2]glucose were used to measure peripheral insulin sensitivity and endogenous glucose production. Muscle and hepatic lipid contents were assessed by (1)H-magnetic resonance spectroscopy, and immune status, cytokines, and endotoxin were measured with specific assays.
RESULTS: In glucose-tolerant volunteers, daily administration of L. reuteri SD5865 increased glucose-stimulated GLP-1 and GLP-2 release by 76% (P < 0.01) and 43% (P < 0.01), respectively, compared with placebo, along with 49% higher insulin (P < 0.05) and 55% higher C-peptide secretion (P < 0.05). However, the intervention did not alter peripheral and hepatic insulin sensitivity, body mass, ectopic fat content, or circulating cytokines.
CONCLUSIONS: Enrichment of gut microbiota with L. reuteri increases insulin secretion, possibly due to augmented incretin release, but does not directly affect insulin sensitivity or body fat distribution. This suggests that oral ingestion of one specific strain may serve as a novel therapeutic approach to improve glucose-dependent insulin release.
© 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26084343     DOI: 10.2337/dc14-2690

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  57 in total

Review 1.  Altered Gut Microbiota in Type 2 Diabetes: Just a Coincidence?

Authors:  Antonio Sircana; Luciana Framarin; Nicola Leone; Mara Berrutti; Francesca Castellino; Renato Parente; Franco De Michieli; Elena Paschetta; Giovanni Musso
Journal:  Curr Diab Rep       Date:  2018-09-13       Impact factor: 4.810

Review 2.  Manipulation of intestinal microbiome as potential treatment for insulin resistance and type 2 diabetes.

Authors:  Yasaman Ghorbani; Katherine J P Schwenger; Johane P Allard
Journal:  Eur J Nutr       Date:  2021-03-02       Impact factor: 5.614

Review 3.  Anxiety, Depression, and the Microbiome: A Role for Gut Peptides.

Authors:  Gilliard Lach; Harriet Schellekens; Timothy G Dinan; John F Cryan
Journal:  Neurotherapeutics       Date:  2018-01       Impact factor: 7.620

Review 4.  Mechanisms Linking the Gut Microbiome and Glucose Metabolism.

Authors:  Kristina M Utzschneider; Mario Kratz; Chris J Damman; Meredith Hullar
Journal:  J Clin Endocrinol Metab       Date:  2016-03-03       Impact factor: 5.958

5.  Microbial lysate upregulates host oxytocin.

Authors:  Bernard J Varian; Theofilos Poutahidis; Brett T DiBenedictis; Tatiana Levkovich; Yassin Ibrahim; Eliska Didyk; Lana Shikhman; Harry K Cheung; Alexandros Hardas; Catherine E Ricciardi; Kumaran Kolandaivelu; Alexa H Veenema; Eric J Alm; Susan E Erdman
Journal:  Brain Behav Immun       Date:  2016-11-05       Impact factor: 7.217

6.  Alginate oligosaccharide improves lipid metabolism and inflammation by modulating gut microbiota in high-fat diet fed mice.

Authors:  Yuting Wang; Lili Li; Changqing Ye; Jingyi Yuan; Song Qin
Journal:  Appl Microbiol Biotechnol       Date:  2020-02-26       Impact factor: 4.813

Review 7.  Gut Microbiota in Cardiovascular Health and Disease.

Authors:  W H Wilson Tang; Takeshi Kitai; Stanley L Hazen
Journal:  Circ Res       Date:  2017-03-31       Impact factor: 17.367

Review 8.  Impacts of gut microbiota on gestational diabetes mellitus: a comprehensive review.

Authors:  Lingling Huang; Chanisa Thonusin; Nipon Chattipakorn; Siriporn C Chattipakorn
Journal:  Eur J Nutr       Date:  2021-01-29       Impact factor: 5.614

9.  Genes Involved in Galactooligosaccharide Metabolism in Lactobacillus reuteri and Their Ecological Role in the Gastrointestinal Tract.

Authors:  Monchaya Rattanaprasert; Jan-Peter van Pijkeren; Amanda E Ramer-Tait; Maria Quintero; Car Reen Kok; Jens Walter; Robert W Hutkins
Journal:  Appl Environ Microbiol       Date:  2019-10-30       Impact factor: 4.792

10.  Improvement in glucose tolerance and insulin sensitivity by probiotic strains of Indian gut origin in high-fat diet-fed C57BL/6J mice.

Authors:  Mahalingam Balakumar; Durai Prabhu; Chandrakumar Sathishkumar; Paramasivam Prabu; Namita Rokana; Ramesh Kumar; Srividhya Raghavan; Avinash Soundarajan; Sunita Grover; Virender Kumar Batish; Viswanathan Mohan; Muthuswamy Balasubramanyam
Journal:  Eur J Nutr       Date:  2016-10-18       Impact factor: 5.614

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.